CN110650961A - Parp抑制剂、其药物组合物、制备方法和应用 - Google Patents

Parp抑制剂、其药物组合物、制备方法和应用 Download PDF

Info

Publication number
CN110650961A
CN110650961A CN201880030303.4A CN201880030303A CN110650961A CN 110650961 A CN110650961 A CN 110650961A CN 201880030303 A CN201880030303 A CN 201880030303A CN 110650961 A CN110650961 A CN 110650961A
Authority
CN
China
Prior art keywords
substituted
group
membered
alkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880030303.4A
Other languages
English (en)
Other versions
CN110650961B (zh
Inventor
许勇
黄璐
胡海
林当
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Dankang Medicine Biological Co ltd
Original Assignee
Guangzhou Dankang Medicine Biological Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Dankang Medicine Biological Co ltd filed Critical Guangzhou Dankang Medicine Biological Co ltd
Publication of CN110650961A publication Critical patent/CN110650961A/zh
Application granted granted Critical
Publication of CN110650961B publication Critical patent/CN110650961B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Abstract

本发明公开了PARP抑制剂、其药物组合物、制备方法和应用。本发明式I所示化合物、其药学上可接受的盐、N‑氧化物、溶剂化物、代谢产物、立体异构体或前药。本发明所述PARP抑制剂提供了一种新的商业选择，可用于治疗和/或预防肿瘤、中风、心肌缺血、炎症或糖尿病。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201880030303.4A 2017-05-08 2018-05-08 Parp抑制剂、其药物组合物、制备方法和应用 Active CN110650961B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017103177844 2017-05-08
CN201710317784 2017-05-08
PCT/CN2018/086061 WO2018205938A1 (zh) 2017-05-08 2018-05-08 Parp抑制剂、其药物组合物、制备方法和应用

Publications (2)

Publication Number Publication Date
CN110650961A true CN110650961A (zh) 2020-01-03
CN110650961B CN110650961B (zh) 2022-09-27

Family

ID=64105090

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880030303.4A Active CN110650961B (zh) 2017-05-08 2018-05-08 Parp抑制剂、其药物组合物、制备方法和应用

Country Status (2)

Country Link
CN (1) CN110650961B (zh)
WO (1) WO2018205938A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110256461B (zh) * 2019-06-20 2020-04-07 江西中医药大学 稠杂嘧啶衍生物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171214A (zh) * 2008-08-06 2011-08-31 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
WO2011130661A1 (en) * 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171214A (zh) * 2008-08-06 2011-08-31 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
WO2011130661A1 (en) * 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma

Also Published As

Publication number Publication date
WO2018205938A1 (zh) 2018-11-15
CN110650961B (zh) 2022-09-27

Similar Documents

Publication Publication Date Title
US10774052B2 (en) Heteroaryl compounds and uses thereof
WO2021073439A1 (zh) 用于抑制shp2活性的吡嗪衍生物
CN106488910B (zh) Kras g12c的抑制剂
JP6592197B2 (ja) アクリル酸誘導体、製造方法、および医薬としてのその使用
CN109415361B (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
CN115448916A (zh) Tyk2抑制剂及其用途
US20180105528A1 (en) Preparation and use of novel protein kinase inhibitors
CN106536503A (zh) 一种酪氨酸激酶抑制剂及其用途
CN111793068A (zh) 杂芳基化合物和其用途
TWI669300B (zh) 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
CN107698575A (zh) cereblon配体介导的新型BET蛋白降解的双功能分子及其制备和应用
CN116535401A (zh) 新的parp1抑制剂及其应用
CN104910137A (zh) Cdk激酶抑制剂
CN106146473B (zh) 一种抗血管新生化合物
CN110650961B (zh) Parp抑制剂、其药物组合物、制备方法和应用
CN109400632B (zh) 一种含n-甲基依诺沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
WO2023024545A1 (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
CN105541792B (zh) 多环类pi3k抑制剂
TWI707853B (zh) 1,2-二氫-1,6-萘啶類衍生物、其製備方法、其藥物組合物及其在醫藥上的用途
CN115843296B (zh) Cdk9抑制剂及其用途
CN114409636B (zh) 一种喹唑啉酮化合物或其药学上可接受的盐及其制备方法和应用
CN108727368A (zh) 含氮稠杂环化合物、其制备方法、中间体、组合物和应用
CN109438481B (zh) 一种含n-甲基莫西沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN109438472B (zh) 一种含n-甲基加替沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用
CN108884104A (zh) 作为免疫调节剂的三并环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant